← All Benitec Biopharma INC filings

Benitec Biopharma INC 8-K filings

NASDAQ
BNTC
Benitec Biopharma INC
8-K: Benitec Biopharma Announces Positive Clinical Trial Data and $40 Million Financing
Benitec Biopharma reported positive interim clinical trial data for its lead candidate BB-301 in OPMD patients and secured $40 million in private financing.
NASDAQ
BNTC
Benitec Biopharma INC
8-K: Benitec Biopharma Secures $40 Million in Oversubscribed Private Placement
Benitec Biopharma has successfully completed a $40 million private placement to advance its clinical programs and for general corporate purposes.
NASDAQ
BNTC
Benitec Biopharma INC
8-K: Benitec Biopharma Announces Positive Interim Data for BB-301 Gene Therapy in OPMD Trial
Benitec Biopharma reported positive interim clinical trial data showing improvements in swallowing function in the first patient treated with BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD).
NASDAQ
BNTC
Benitec Biopharma INC
8-K: Benitec Biopharma Grants Executive Stock Options to CEO and Executive Director
Benitec Biopharma's Compensation Committee approved stock option grants to its CEO and Executive Director on March 6, 2024.
NASDAQ
BNTC
Benitec Biopharma INC
8-K: Benitec Biopharma Reports Second Quarter 2024 Financials and Provides Clinical Trial Update
Benitec Biopharma announced its second quarter 2024 financial results and provided an update on its BB-301 clinical trial for Oculopharyngeal Muscular Dystrophy, including the dosing of the first subject and the scheduling of the second.